The coverage landscape in 2026
GLP-1 insurance coverage depends on three things: what the medication is prescribed for (diabetes vs. weight loss), what type of insurance plan you have, and which specific medication your provider prescribes. The same molecule — semaglutide — is covered differently depending on whether it's Ozempic (diabetes, ~85% commercial coverage) or Wegovy (weight loss, ~45% commercial coverage).
Commercial insurance (employer-sponsored and marketplace)
Coverage varies dramatically by plan. Some employer plans specifically exclude weight loss medications to control costs. Others have expanded coverage, particularly since the SELECT trial showed cardiovascular benefits for Wegovy. In 2026, the trend is toward increasing coverage, but there are significant gaps.
Most commercial plans that cover GLP-1s for weight loss require prior authorization, which typically involves documented BMI ≥30 (or ≥27 with comorbidities), evidence of prior weight management attempts (often 6+ months of documented diet/exercise), and specific clinical documentation from your prescribing provider. The prior authorization process takes 5–15 business days for standard requests. Urgent requests can be processed in 24–72 hours.
Some plans impose step therapy — requiring you to try a less expensive medication first (like Contrave or Saxenda) before approving a GLP-1. If this applies to you, your provider can sometimes submit documentation showing clinical justification for skipping the step therapy requirement.
Medicare
Historically, Medicare Part D has been prohibited from covering anti-obesity medications. This is changing in 2026 with the Medicare GLP-1 Bridge program, launching July 1, 2026, through December 31, 2027. Eligible beneficiaries can access Wegovy, Zepbound, and other covered GLP-1 medications for approximately $50 per month. Eligibility requires meeting specific clinical criteria across three tiers (see our Medicare GLP-1 Bridge article for details).
Medicare already covers Ozempic and Mounjaro when prescribed for type 2 diabetes.
Manufacturer savings programs
Both Novo Nordisk and Eli Lilly offer savings programs that can dramatically reduce out-of-pocket costs for patients with commercial insurance.
Wegovy Savings Card: Eligible commercially insured patients may pay as low as $25/mo, with savings capped at $100/mo off the copay.
NovoCare Cash-Pay: Wegovy at $349/mo ($199/mo for starter doses through June 2026). Available to uninsured patients.
Zepbound Savings Card: Eligible commercially insured patients may pay as low as $25/mo.
LillyDirect Cash-Pay: Zepbound starting at $349/mo. Available to uninsured patients.
Important: these savings cards do not apply to government insurance (Medicare, Medicaid, Tricare, VA). They apply only to patients with commercial insurance or those paying cash.
When insurance isn't an option
If your insurance doesn't cover GLP-1 medications and cash-pay brand-name pricing ($349–$499/mo) is out of reach, compounded GLP-1 medications through telehealth providers offer a more affordable path at $149–$299/mo. Compounded medications are not FDA-approved and are not covered by insurance, but they contain the same active ingredients (semaglutide or tirzepatide) at a fraction of the cost. See our provider comparison page for vetted options.
HSA and FSA
GLP-1 medications — both brand-name and compounded — are generally eligible expenses for Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) when prescribed to treat a diagnosed medical condition (obesity, type 2 diabetes). The IRS classifies weight loss programs and medications as eligible expenses when they treat a specific diagnosed disease. Keep your prescription documentation and Letter of Medical Necessity from your provider for your records.